Luye Pharma Group Reports H1 2023 Revenue Growth with Strong Oncology and CNS Sales
China-based Luye Pharma Group (HKG: 2186) has announced its financial performance for the first half...
Finanical Reports
Lundbeck A/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales
Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has released its financial report for the...
Harbour BioMed Reports First Profitable Half-Year in H1 2023 Financial Results
China-based Harbour BioMed (HKG: 2142) has released its interim financial report for the first half...
Luye Pharma Group’s Subsidiary Boan Biotechnology Reports 18.4% Revenue Growth in H1 2023
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955),...
3SBio Inc. Reports H1 2023 Revenue Growth and Expansion in Digital Marketing
China-based 3SBio Inc. (HKG: 1530) has released its financial report for the first half of...
Innovent Biologics Reports 20.6% YOY Revenue Growth in H1 2023 Financials
China-based Innovent Biologics Inc., (HKG: 1801) has released its financial results for the first half...
WuXi Biologics Reports 17.8% Revenue Growth and Expands Service Scope in H1 2023
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has released its...
Everest Medicines Reports Q1 2023 Revenue Growth and Pipeline Progress
China-based Everest Medicines (HKG: 1952) has announced its financial and corporate update for the first...
RemeGen Ltd Reports 20.56% YOY Revenue Growth in H1 2023 Financial Results
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has released its financial report for the first...
Ascentage Pharma’s 2023 Interim Report: 49% YOY Revenue Growth and Market Expansion
China-based Ascentage Pharma (HKG: 6855) has released its 2023 interim financial report, revealing a 49%...
Ascletis Pharma Inc. Reports 21.7% Revenue Increase in H1 2023, Led by Ritonavir Sales
China-based Ascletis Pharma Inc., (HKG: 1672) has revealed revenues of RMB 46.51 million (USD 6.38...
New Horizon Health Ltd Reports 264.6% YOY Revenue Increase and First Recurring Profits
China-based New Horizon Health Ltd (HKG: 6606), a leading cancer diagnostics developer, has released its...
Jiangsu Hengrui Pharmaceuticals Reports 9.19% YOY Revenue Growth in H1 2023 Financial Report
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has released its financial report for the first...
JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report
JD Healthcare, a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD), has released its 2023...
Sinovac Biotech Reports H1 2023 Financials with Significant Sales Decline from COVID-19 Boom
Sinovac Biotech Ltd (NASDAQ: SVA) has published its financial results for the first half of...
Gracell Biotechnologies Reports Q2 2023 Financials, Highlights GC012F in Melanoma Treatment
Suzhou-based biotech company Gracell Biotechnologies Inc., (NASDAQ: GRCL) has reported its financial results for the...
Legend Biotech Corporation Reports Q2 and H1 2023 Financials with Increased Revenues and R&D Spending
Legend Biotech Corporation (NASDAQ: LEGN) has released its financial results for the second quarter and...
Novo Nordisk’s H1 2023 Financials Show 30% YOY Growth Driven by GLP-1 Drugs and Obesity Sales
Denmark-based pharmaceutical company Novo Nordisk A/S (NYSE: NVO) has announced its financial results for the...
Organon Reports Q2 2023 Revenue Growth, Driven by Women’s Health and Biosimilars
US-based Organon (NYSE: OGN) has reported its financial results for the second quarter of 2023,...
Denali Therapeutics and Takeda Halt Development of Alzheimer’s Drug Candidate TAK-920/DNL919
US-based biopharmaceutical company Denali Therapeutics Inc., (NASDAQ: DNLI) has announced in its Q2 2023 financial...